Editas Medicine (EDIT) PT Lowered to $4 at RBC Capital on Lead Program Termination
Tweet Send to a Friend
RBC Capital analyst Luca Issi lowered the price target on Editas Medicine (NASDAQ: EDIT) to $4.00 (from $5.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
